Viking Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Annual Cantor Global Health Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum in September.

PRNewsWire • 2 hours ago

Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.

VK2735 is Viking's lead candidate for obesity with dual-formulation potential. Major trial results are years away, so volatility is likely, but upcoming trial data could shift sentiment in the near term.

The Motley Fool • Aug 30, 2026

Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?

Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Aug 28, 2026

Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?

Viking's strong cash position funds operations through major milestones in 2027 and 2028. VK2735's dual-formulation strategy and upcoming dosing data will be important for 2026.

The Motley Fool • Aug 27, 2026

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.

Zacks Investment Research • Aug 17, 2026

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeutics' leading GLP-1 candidate looks very promising.

The Motley Fool • Aug 8, 2026

Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)

Viking Therapeutics (VKTX) maintains a Hold rating as competitive pressures intensify in the GLP-1 obesity drug space and key data catalysts approach. VKTX's lead asset VK2735 is in large Phase 3 VANQUISH trials, but efficacy expectations are high, and prior data is limited to a small, short Phase 2 study. A pivotal Q3 catalyst is the maintenance dosing study for VK2735; results could drive price volatility and influence funding needs amid high cash burn.

Seeking Alpha • Aug 7, 2026

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Cash burn and potential dilution are key investor concerns. The company's phase 3 trials remain on track, and investors are awaiting results from a maintenance trial this quarter.

The Motley Fool • Aug 6, 2026

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

Viking Therapeutics' pipeline in weight management could make it a great acquisition target. The biotech's prospects in this area look somewhat promising, but there's significant risk involved.

The Motley Fool • Jul 30, 2026

VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs

Viking Therapeutics beats second-quarter loss estimates as it advances late-stage obesity studies despite sharply higher R&D spending tied to its expanding pipeline.

Zacks Investment Research • Jul 30, 2026